DIFFUSE MIDLINE GLIOMA

This study tests a personalized DNA vaccine for children and young adults (ages 12-25) with central nervous system tumors that have come back or not responded to treatment. The vaccine is made from each patient's unique tumor DNA to train the immune system to fight the cancer. Th…

This study tests a new treatment called BCB-276 for children and young adults with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. BCB-276 is made from a patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The tr…

This early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…

This study tests an oral drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose in up to 18 children, then testing that …

This study tests whether a special PET scan called 18F-Fluciclovine can help doctors tell the difference between actual tumor growth and harmless changes caused by treatment in children with high-grade glioma. About 30 children aged 1 to 21 will receive the scan after radiation t…

This study creates a central registry and tissue bank for people with DIPG or DMG, rare and aggressive brain tumors. Researchers will collect medical information, scans, and tumor samples from up to 1,500 patients of any age. The goal is to understand the biology of these tumors …